Gruppo Oncologico Del Nord-ovest

This study is testing whether a postbiotic supplement can help patients with advanced head and neck cancer better tolerate their immunotherapy treatment. Forty-five patients receiving standard pembrolizumab will be randomly assigned to also take either the postbiotic or a placebo…

This large, late-stage trial is testing if adding an immunotherapy drug (atezolizumab) to a standard, strong chemotherapy combination can better control advanced colorectal cancer that has spread and cannot be surgically removed. It will enroll about 238 patients with specific tu…

This study is testing a new first-line treatment for people with advanced, HER2-positive colorectal cancer that cannot be removed by surgery. It combines three drugs—trastuzumab-deruxtecan, capecitabine, and bevacizumab—to see how well they shrink tumors and control the disease. …

This study is testing whether giving a short course of targeted drugs before surgery can better control colorectal cancer. It enrolls patients with non-metastatic, operable cancer and matches them to a specific drug based on the unique genetic markers found in their tumor. The ma…